Identification

Name
Clomipramine
Accession Number
DB01242  (APRD00253, DB07600)
Type
Small Molecule
Groups
Approved, Investigational, Vet approved
Description

Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Clomipramine may be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette’s disorder). Unlabeled indications include panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy, autistic disorder, trichotillomania, onchophagia, stuttering, premature ejaculation, and premenstrual syndrome. Clomipramine is rapidly absorbed from the gastrointestinal tract and demethylated in the liver to its primary active metabolite, desmethylclomipramine.

Structure
Thumb
Synonyms
  • 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamine
  • 3-(3-chloro-5H-dibenzo[b,F]azepin-5-yl)-N,N-dimethylpropan-1-amine
  • 3-Chloroimipramine
  • Chlorimipramine
  • Clomipramina
  • Clomipraminum
  • Monochlorimipramine
External IDs
NSC-169865
Product Ingredients
IngredientUNIICASInChI Key
Clomipramine hydrochloride2LXW0L6GWJ17321-77-6WIMWMKZEIBHDTH-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act ClomipramineTablet10 mgOralActavis Pharma Company2003-02-202016-02-19Canada
Act ClomipramineTablet50 mgOralActavis Pharma Company2003-02-202016-02-19Canada
Act ClomipramineTablet25 mgOralActavis Pharma Company2003-02-202016-02-19Canada
AnafranilTablet50 mgOralAa Pharma Inc1981-12-31Not applicableCanada
AnafranilCapsule50 mg/1OralSpec Gx Llc2011-03-18Not applicableUs
AnafranilTablet10 mgOralAa Pharma Inc1975-12-31Not applicableCanada
AnafranilCapsule25 mg/1OralSpec Gx Llc2011-03-18Not applicableUs
AnafranilCapsule75 mg/1OralSpec Gx Llc2011-03-18Not applicableUs
AnafranilTablet25 mgOralAa Pharma Inc1973-12-31Not applicableCanada
Clomipramine HydrochlorideCapsule50 mg/1OralSpec Gx Llc2015-06-01Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Altius-clomipramineTablet25 mgOralAspri Pharma Canada IncNot applicableNot applicableCanada
Altius-clomipramineTablet10 mgOralAspri Pharma Canada IncNot applicableNot applicableCanada
Altius-clomipramineTablet50 mgOralAspri Pharma Canada IncNot applicableNot applicableCanada
Apo-clomipramine Tablets 10mgTablet10 mgOralApotex Corporation1993-12-312016-06-30Canada
Apo-clomipramine Tablets 25mgTablet25 mgOralApotex Corporation1993-12-312016-06-30Canada
Apo-clomipramine Tablets 50mgTablet50 mgOralApotex Corporation1993-12-312016-06-30Canada
Clomipramine HydrochlorideCapsule50 mg/1OralMylan Pharmaceuticals1998-05-11Not applicableUs
Clomipramine HydrochlorideCapsule50 mg/1OralCadila Pharnmaceuticals2018-05-03Not applicableUs
Clomipramine HydrochlorideCapsule25 mg/1OralTaro Pharmaceuticals U.S.A., Inc.1996-12-31Not applicableUs51672 4011 05 nlmimage10 f804fc47
Clomipramine HydrochlorideCapsule75 mg/1OralSandoz1996-03-29Not applicableUs
International/Other Brands
Anapramine / Hydiphen (Arzneimittelwerk Dresden)
Categories
UNII
NUV44L116D
CAS number
303-49-1
Weight
Average: 314.852
Monoisotopic: 314.154976453
Chemical Formula
C19H23ClN2
InChI Key
GDLIGKIOYRNHDA-UHFFFAOYSA-N
InChI
InChI=1S/C19H23ClN2/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3
IUPAC Name
(3-{14-chloro-2-azatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,12,14-hexaen-2-yl}propyl)dimethylamine
SMILES
CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2

Pharmacology

Indication

May be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette’s disorder). Unlabeled indications include: depression, panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy (limited evidence), autistic disorder (limited evidence), trichotillomania (limited evidence), onchophagia (limited evidence), stuttering (limited evidence), premature ejaculation, and premenstrual syndrome.

Associated Conditions
Pharmacodynamics

Clomipramine, a tricyclic antidepressant, is the 3-chloro derivative of Imipramine. It was thought that tricyclic antidepressants work exclusively by inhibiting the re-uptake of the neurotransmitters norepinephrine and serotonin by nerve cells. However, this response occurs immediately, yet mood does not lift for around two weeks. It is now thought that changes occur in receptor sensitivity in the cerebral cortex and hippocampus. The hippocampus is part of the limbic system, a part of the brain involved in emotions. Presynaptic receptors are affected: α1 and β1 receptors are sensitized, α2 receptors are desensitized (leading to increased noradrenaline production). Tricyclics are also known as effective analgesics for different types of pain, especially neuropathic or neuralgic pain.

Mechanism of action

Clomipramine is a strong, but not completely selective serotonin reuptake inhibitor (SRI), as the active main metabolite desmethyclomipramine acts preferably as an inhibitor of noradrenaline reuptake. α1-receptor blockage and β-down-regulation have been noted and most likely play a role in the short term effects of clomipramine. A blockade of sodium-channels and NDMA-receptors might, as with other tricyclics, account for its effect in chronic pain, in particular the neuropathic type.

TargetActionsOrganism
ASodium-dependent serotonin transporter
inhibitor
Human
A5-hydroxytryptamine receptor 2A
antagonist
Human
A5-hydroxytryptamine receptor 2B
antagonist
Human
A5-hydroxytryptamine receptor 2C
antagonist
Human
USodium-dependent noradrenaline transporter
inhibitor
Human
UGlutathione S-transferase P
inhibitor
Human
Absorption

Well absorbed from the GI tract following oral administration. Bioavailability is approximately 50% orally due to extensive first-pass metabolism. Bioavailability is not affected by food. Peak plasma concentrations occurred 2-6 hours following oral administration of a single 50 mg dose. The peak plasma concentration ranged from 56 ng/mL to 154 mg/mL (mean, 92 ng/mL). There are large interindividual variations in plasma concentrations occur, partly due to genetic differences in clomipramine metabolism. On average, steady state plasma concentrations are achieved in 1-2 weeks following multiple dose oral administration. Smoking appears to lower the steady-state plasma concentration of clomipramine, but not its active metabolite desmethylclomipramine.

Volume of distribution

~ 17 L/kg (range: 9-25 L/kg). Clomipramine is capable of distributing into the cerebrospinal fluid, the brain, and into breast milk.

Protein binding

Clomipramine is approximately 97-98% bound to plasma proteins, principally to albumin and possibly to α1-acid glycoprotein. Desmethylclomipramine is 97-99% bound to plasma proteins.

Metabolism

Extensively metabolized in the liver. The main active metabolite is desmethylclomipramine, which is formed by N-demethylation of clomipramine via CYP2C19, 3A4 and 1A2. Other metabolites and their glucuronide conjugates are also produced. Other metabolites of clomipramine include 8-hydroxyclomipramine formed via 8-hydroxylation, 2-hydroxyclomipramine formed via 2-hydroxylation, and clomipramine N-oxide formed by N-oxidation. Desmethylclomipramine is further metabolized to 8-hydroxydesmethylclomipramine and didesmethylclomipramine, which are formed by 8-hydroxylation and N-demethylation, respectively. 8-Hydroxyclomipramine and 8-hydroxydesmethylclomipramine are pharmacologically active; however, their clinical contribution remains unknown.

Route of elimination

Urine (51-60%) and feces via biliary elimination (24-32%)

Half life

Following oral administration of a single 150 mg dose of clomipramine, the average elimination half-life of clomipramine was 32 hours (range: 19-37 hours) and of desmethylclomipramine was 69 hours (range: 54-77 hours). Elimination half-life may vary substantially with different doses due to saturable kinetics (i.e. metabolism).

Clearance
Not Available
Toxicity

Signs and symptoms vary in severity depending upon factors such as the amount of drug absorbed, the age of the patient, and the time elapsed since drug ingestion. Critical manifestations of overdose include cardiac dysrhythmias, severe hypotension, convulsions, and CNS depression including coma. Changes in the electrocardiogram, particularly in QRS axis or width, are clinically significant indicators of tricyclic toxicity. In U.S. clinical trials, 2 deaths occurred in 12 reported cases of acute overdosage with Anafranil either alone or in combination with other drugs. One death involved a patient suspected of ingesting a dose of 7000 mg. The second death involved a patient suspected of ingesting a dose of 5750 mg. Side effects include: sedation, hypotension, blurred vision, dry mouth, constipation, urinary retention, postural hypotension, tachycardia, hypertension, ECG changes, heart failure, impaired memory and delirium, and precipitation of hypomanic or manic episodes in bipolar depression. Withdrawal symptoms include gastrointestinal disturbances, anxiety, and insomnia.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Clomipramine Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2D6CYP2D6*4(A;A)A AlleleEffect Directly StudiedPatients with this genotype have reduced metabolism of clomipramine.Details
Cytochrome P450 2D6CYP2D6*3Not Available2549delAEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of clomipramine.Details
Cytochrome P450 2D6CYP2D6*4Not AvailableA alleleEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of clomipramine.Details
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of clomipramine.Details
Cytochrome P450 2D6CYP2D6*6Not Available1707delTEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of clomipramine.Details
Cytochrome P450 2C19CYP2C19*2Not Available681G>AEffect Directly StudiedThe presence of this polymorphism in CYP2C19 is associated with poor metabolism of clomipramine.Details
Cytochrome P450 2C19CYP2C19*3Not Available636G>AEffect Directly StudiedThe presence of this polymorphism in CYP2C19 is associated with reduced or poor metabolism of clomipramine.Details
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*11Not Available883G>CEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*12Not Available124G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*2ANot Available681G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*2BNot Available681G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*4Not Available1A>GEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*5Not Available1297C>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*6Not Available395G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*7Not Available19294T>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*22Not Available557G>C / 991A>GEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*24Not Available99C>T / 991A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*35Not Available12662A>GEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*3Not AvailableC alleleEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*6Not Available1707delTEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*11Not Available883G>CEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*12Not Available124G>AEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*3Not AvailableG alleleEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of clomipramine.Details
Cytochrome P450 2D6CYP2D6*4Not Available3877G>AEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of clomipramine.Details

Interactions

Drug Interactions
DrugInteractionDrug group
(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINEThe serum concentration of Clomipramine can be increased when it is combined with (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE.Experimental
1,10-PhenanthrolineThe serum concentration of Clomipramine can be increased when it is combined with 1,10-Phenanthroline.Experimental
2,5-Dimethoxy-4-ethylamphetamineClomipramine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineClomipramine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-DichloroisocoumarinThe serum concentration of Clomipramine can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
3,4-MethylenedioxyamphetamineClomipramine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Clomipramine can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
4-Bromo-2,5-dimethoxyamphetamineClomipramine may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineClomipramine may decrease the antihypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Clomipramine is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Clomipramine.Experimental
AbediterolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Abediterol.Investigational
AbirateroneThe serum concentration of Clomipramine can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Clomipramine is combined with Acebutolol.Approved, Investigational
AcenocoumarolClomipramine may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Clomipramine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Clomipramine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Clomipramine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Acetophenazine.Approved
Acetyl sulfisoxazoleThe metabolism of Clomipramine can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Clomipramine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Clomipramine is combined with Adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Clomipramine.Approved
AgmatineClomipramine may decrease the antihypertensive activities of Agmatine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Agomelatine.Approved, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Clomipramine.Approved, Investigational
AlaproclateAlaproclate may increase the serotonergic activities of Clomipramine.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Clomipramine is combined with Aldesleukin.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Clomipramine.Approved, Illicit
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Clomipramine.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Clomipramine is combined with Aliskiren.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Clomipramine.Approved, Investigational
AlogliptinThe serum concentration of Clomipramine can be increased when it is combined with Alogliptin.Approved
AlosetronAlosetron may increase the serotonergic activities of Clomipramine.Approved, Withdrawn
Alpha-1-proteinase inhibitorThe serum concentration of Clomipramine can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Clomipramine.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Clomipramine.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Clomipramine.Approved
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Clomipramine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Clomipramine is combined with Amiloride.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Clomipramine.Approved, Withdrawn
AmiodaroneThe metabolism of Clomipramine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Clomipramine is combined with Amisulpride.Approved, Investigational
AmitrazClomipramine may decrease the antihypertensive activities of Amitraz.Vet Approved
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Clomipramine.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Amlodipine.Approved
AmobarbitalThe metabolism of Clomipramine can be increased when combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Clomipramine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Clomipramine is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the serotonergic activities of Clomipramine.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Clomipramine.Approved, Investigational
AmprenavirThe serum concentration of Clomipramine can be increased when it is combined with Amprenavir.Approved, Investigational
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Clomipramine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Clomipramine is combined with Amyl Nitrite.Approved
AnagrelideClomipramine may increase the QTc-prolonging activities of Anagrelide.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Clomipramine.Approved, Investigational
Antithrombin III humanThe serum concentration of Clomipramine can be increased when it is combined with Antithrombin III human.Approved
ApalutamideThe serum concentration of Clomipramine can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe serum concentration of Clomipramine can be increased when it is combined with Apixaban.Approved
ApomorphineClomipramine may decrease the antihypertensive activities of Apomorphine.Approved, Investigational
ApraclonidineClomipramine may decrease the antihypertensive activities of Apraclonidine.Approved
AprepitantThe serum concentration of Clomipramine can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Clomipramine.Approved
AprotininThe serum concentration of Clomipramine can be increased when it is combined with Aprotinin.Approved, Investigational, Withdrawn
ArbutamineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Arbutamine.Approved
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Clomipramine.Approved, Investigational
ArgatrobanThe serum concentration of Clomipramine can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Clomipramine.Approved, Investigational
ArmodafinilThe metabolism of Clomipramine can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Clomipramine.Investigational
Arsenic trioxideClomipramine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherClomipramine may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Articaine.Approved
AsenapineClomipramine may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Clomipramine.Approved, Withdrawn
AsunaprevirThe serum concentration of Clomipramine can be increased when it is combined with Asunaprevir.Approved, Investigational, Withdrawn
AtazanavirThe metabolism of Clomipramine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Clomipramine is combined with Atenolol.Approved
AtomoxetineThe metabolism of Clomipramine can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Azaperone.Investigational, Vet Approved
AzelastineClomipramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Clomipramine is combined with Azilsartan medoxomil.Approved, Investigational
AzithromycinThe metabolism of Clomipramine can be decreased when combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Clomipramine.Approved
BambuterolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Bambuterol.Approved, Investigational
BarbexacloneThe metabolism of Clomipramine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Clomipramine can be increased when combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Clomipramine.Approved
BatimastatThe serum concentration of Clomipramine can be increased when it is combined with Batimastat.Experimental
BedaquilineClomipramine may increase the QTc-prolonging activities of Bedaquiline.Approved
BenazeprilThe serum concentration of Clomipramine can be increased when it is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Clomipramine is combined with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the serotonergic activities of Clomipramine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Benperidol.Approved, Investigational
BenzamidineThe serum concentration of Clomipramine can be increased when it is combined with Benzamidine.Experimental
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Clomipramine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Benzocaine.Approved, Investigational
BenzphetamineClomipramine may decrease the antihypertensive activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Clomipramine.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Clomipramine.Approved, Withdrawn
BetaxololThe metabolism of Betaxolol can be decreased when combined with Clomipramine.Approved, Investigational
BethanidineClomipramine may decrease the antihypertensive activities of Bethanidine.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Clomipramine is combined with Bifeprunox.Investigational
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Clomipramine.Approved
BitolterolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Bitolterol.Withdrawn
BivalirudinThe serum concentration of Clomipramine can be increased when it is combined with Bivalirudin.Approved, Investigational
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Clomipramine.Investigational
BoceprevirThe metabolism of Clomipramine can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Clomipramine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Clomipramine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Clomipramine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Clomipramine.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Clomipramine is combined with Bretylium.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Clomipramine.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.Approved
BrofaromineBrofaromine may increase the serotonergic activities of Clomipramine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Clomipramine.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Clomipramine is combined with Bromisoval.Experimental
BromocriptineClomipramine may decrease the antihypertensive activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Clomipramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Clomipramine is combined with Brotizolam.Approved, Investigational, Withdrawn
BufuralolThe metabolism of Bufuralol can be decreased when combined with Clomipramine.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Clomipramine is combined with Bumetanide.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Clomipramine.Approved, Investigational
BuprenorphineClomipramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Clomipramine can be decreased when combined with Bupropion.Approved
BuspironeBuspirone may increase the serotonergic activities of Clomipramine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Clomipramine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Clomipramine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Clomipramine is combined with Butamben.Approved, Withdrawn
ButaperazineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Clomipramine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Clomipramine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Clomipramine.Approved
CaffeineThe metabolism of Clomipramine can be decreased when combined with Caffeine.Approved
CamostatThe serum concentration of Clomipramine can be increased when it is combined with Camostat.Experimental
CanagliflozinThe risk or severity of adverse effects can be increased when Clomipramine is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Clomipramine is combined with Candesartan cilexetil.Approved
CandoxatrilThe serum concentration of Clomipramine can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Clomipramine can be increased when it is combined with Candoxatrilat.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Clomipramine is combined with Canertinib.Investigational
CaptoprilThe serum concentration of Clomipramine can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Clomipramine can be increased when it is combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Clomipramine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Clomipramine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Clomipramine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Clomipramine.Approved, Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Clomipramine.Approved
CaroxazoneCaroxazone may increase the serotonergic activities of Clomipramine.Withdrawn
CarteololThe metabolism of Carteolol can be decreased when combined with Clomipramine.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Clomipramine.Approved, Investigational
CelecoxibThe metabolism of Clomipramine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololThe risk or severity of adverse effects can be increased when Clomipramine is combined with Celiprolol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Clomipramine.Approved, Investigational, Vet Approved
CeritinibThe serum concentration of Clomipramine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Clomipramine.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Clomipramine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Clomipramine is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChloramphenicolThe metabolism of Clomipramine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Clomipramine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Clomipramine.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Clomipramine is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Clomipramine.Approved
ChlorphentermineClomipramine may increase the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Chlorproethazine is combined with Clomipramine.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Clomipramine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Chlorthalidone.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Clomipramine.Approved
CholecalciferolThe metabolism of Clomipramine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
ChymostatinThe serum concentration of Clomipramine can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Clomipramine can be increased when it is combined with Cilastatin.Approved, Investigational
CilazaprilThe serum concentration of Clomipramine can be increased when it is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Clomipramine.Approved, Investigational
CilostazolThe metabolism of Cilostazol can be decreased when combined with Clomipramine.Approved, Investigational
CimetidineThe metabolism of Clomipramine can be decreased when combined with Cimetidine.Approved, Investigational
CinacalcetThe serum concentration of Clomipramine can be increased when it is combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Cinchocaine.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Clomipramine.Approved, Investigational
CiprofloxacinClomipramine may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CirazolineClomipramine may increase the vasopressor activities of Cirazoline.Experimental
CisaprideClomipramine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of adverse effects can be increased when Clomipramine is combined with Citalopram.Approved
ClarithromycinThe metabolism of Clomipramine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Clomipramine can be decreased when combined with Clemastine.Approved, Investigational
ClenbuterolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Clomipramine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Clomipramine.Approved
ClobazamThe metabolism of Clomipramine can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Clomipramine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Clomipramine is combined with clomethiazole.Investigational
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Clomipramine.Approved, Illicit
ClonidineClomipramine may decrease the antihypertensive activities of Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Clomipramine.Approved, Illicit
ClorindioneClomipramine may increase the anticoagulant activities of Clorindione.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Clomipramine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Clozapine.Approved
CobicistatThe serum concentration of Clomipramine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Clomipramine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Clomipramine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Clomipramine.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Clomipramine.Approved, Investigational
CrizotinibThe metabolism of Clomipramine can be decreased when combined with Crizotinib.Approved
CurcuminThe metabolism of Clomipramine can be decreased when combined with Curcumin.Approved, Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Clomipramine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clomipramine.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Clomipramine.Approved, Investigational
CyclopropaneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Cyclopropane.Experimental
CyclosporineThe metabolism of Clomipramine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Clomipramine.Approved
Cyproterone acetateThe serum concentration of Clomipramine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Clomipramine.Approved
DabrafenibThe serum concentration of Clomipramine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Clomipramine.Approved, Investigational
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Clomipramine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Clomipramine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Clomipramine.Investigational
DarexabanThe serum concentration of Clomipramine can be increased when it is combined with Darexaban.Investigational
DarifenacinThe metabolism of Clomipramine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Clomipramine can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Clomipramine.Approved
DasatinibThe serum concentration of Clomipramine can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Clomipramine.Approved, Investigational
DeferasiroxThe serum concentration of Clomipramine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelanzomibThe serum concentration of Clomipramine can be increased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Clomipramine can be increased when it is combined with Delapril.Investigational
DelavirdineThe metabolism of Clomipramine can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Clomipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Clomipramine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Clomipramine is combined with Desmopressin.Approved
DesvenlafaxineDesvenlafaxine may increase the serotonergic activities of Clomipramine.Approved, Investigational
DetomidineClomipramine may decrease the antihypertensive activities of Detomidine.Vet Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Clomipramine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clomipramine.Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Clomipramine.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Clomipramine.Approved, Illicit, Investigational, Withdrawn
DexmedetomidineClomipramine may decrease the antihypertensive activities of Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Clomipramine.Approved, Investigational
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Clomipramine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Clomipramine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Clomipramine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Clomipramine.Approved, Illicit, Investigational, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Clomipramine is combined with Diclofenamide.Approved, Investigational
DicoumarolClomipramine may increase the anticoagulant activities of Dicoumarol.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Clomipramine is combined with Diethyl ether.Experimental
DiethylpropionClomipramine may increase the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Clomipramine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Clomipramine.Approved, Illicit
DihydroergotamineClomipramine may decrease the antihypertensive activities of Dihydroergotamine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Clomipramine can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Clomipramine.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Clomipramine is combined with Dinutuximab.Approved, Investigational
DiphenadioneClomipramine may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Clomipramine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Clomipramine.Approved, Illicit
DipivefrinClomipramine may decrease the antihypertensive activities of Dipivefrin.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Clomipramine is combined with Dipyridamole.Approved
DisopyramideClomipramine may increase the QTc-prolonging activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Dixyrazine.Experimental
DL-MethylephedrineClomipramine may decrease the antihypertensive activities of DL-Methylephedrine.Approved
DobutamineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Dobutamine.Approved
DofetilideClomipramine may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
DolasetronThe metabolism of Dolasetron can be decreased when combined with Clomipramine.Approved, Investigational
DomperidoneClomipramine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Clomipramine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Clomipramine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Clomipramine is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Clomipramine can be decreased when combined with Dosulepin.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Clomipramine.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Clomipramine.Approved, Investigational
DoxofyllineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Doxofylline.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Clomipramine.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Clomipramine.Approved, Investigational
DoxycyclineThe metabolism of Clomipramine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Clomipramine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.Approved, Illicit
DronedaroneClomipramine may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Drotebanol.Experimental, Illicit
DroxidopaClomipramine may decrease the antihypertensive activities of Droxidopa.Approved, Investigational
DuloxetineDuloxetine may increase the serotonergic activities of Clomipramine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Dyclonine.Approved
EcabetThe serum concentration of Clomipramine can be increased when it is combined with Ecabet.Approved, Investigational
EcgonineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Clomipramine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Clomipramine.Approved
EfavirenzThe metabolism of Clomipramine can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Efonidipine.Approved, Investigational
ElafinThe serum concentration of Clomipramine can be increased when it is combined with Elafin.Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Clomipramine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Clomipramine.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Eltanolone.Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Clomipramine is combined with Empagliflozin.Approved
EnalaprilThe serum concentration of Clomipramine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Clomipramine can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Clomipramine can be increased when it is combined with Enalkiren.Experimental
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Clomipramine.Approved, Investigational
EncainideThe metabolism of Encainide can be decreased when combined with Clomipramine.Approved, Investigational, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Clomipramine.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Clomipramine.Approved, Investigational
EnzalutamideThe serum concentration of Clomipramine can be decreased when it is combined with Enzalutamide.Approved
EphedraClomipramine may decrease the antihypertensive activities of Ephedra.Approved, Nutraceutical, Withdrawn
EpinastineThe metabolism of Epinastine can be decreased when combined with Clomipramine.Approved, Investigational
EpinephrineClomipramine may decrease the antihypertensive activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Clomipramine is combined with Eprosartan.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Clomipramine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Ergonovine.Approved
ErgotamineClomipramine may decrease the antihypertensive activities of Ergotamine.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Clomipramine.Approved, Investigational
ErythromycinThe metabolism of Clomipramine can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Clomipramine is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Clomipramine can be decreased when combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Clomipramine.Investigational
EsmololThe risk or severity of adverse effects can be increased when Clomipramine is combined with Esmolol.Approved
EsomeprazoleThe metabolism of Clomipramine can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Clomipramine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Clomipramine.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Clomipramine is combined with Etacrynic acid.Approved, Investigational
EtafedrineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Etafedrine.Approved
EthanolClomipramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Clomipramine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Clomipramine.Approved
Ethyl biscoumacetateClomipramine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Clomipramine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Clomipramine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Clomipramine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Clomipramine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Clomipramine is combined with Etizolam.Approved
EtomidateClomipramine may decrease the antihypertensive activities of Etomidate.Approved
EtoperidoneEtoperidone may increase the serotonergic activities of Clomipramine.Withdrawn
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Clomipramine.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe metabolism of Clomipramine can be decreased when combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Clomipramine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Ezogabine.Approved, Investigational
FaldaprevirThe serum concentration of Clomipramine can be increased when it is combined with Faldaprevir.Investigational
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Clomipramine.Approved
FelodipineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Clomipramine is combined with Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Clomipramine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Clomipramine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Clomipramine.Approved, Investigational
FimasartanThe risk or severity of adverse effects can be increased when Clomipramine is combined with Fimasartan.Approved, Investigational
FingolimodThe metabolism of Fingolimod can be decreased when combined with Clomipramine.Approved, Investigational
FlecainideThe metabolism of Flecainide can be decreased when combined with Clomipramine.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Clomipramine is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Clomipramine can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Clomipramine is combined with Fludiazepam.Approved, Illicit
FluindioneClomipramine may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Clomipramine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Clomipramine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Clomipramine.Approved, Vet Approved
FlupentixolClomipramine may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Clomipramine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Clomipramine.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Clomipramine.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Clomipramine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Clomipramine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Clomipramine.Approved, Investigational
FosamprenavirThe serum concentration of Clomipramine can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Clomipramine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Clomipramine can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Clomipramine can be increased when combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Fospropofol.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Clomipramine.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Clomipramine.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Clomipramine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Clomipramine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Clomipramine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Clomipramine is combined with Gabapentin Enacarbil.Approved, Investigational
GabexateThe serum concentration of Clomipramine can be increased when it is combined with Gabexate.Investigational
Gadobenic acidClomipramine may increase the QTc-prolonging activities of Gadobenic acid.Approved, Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Clomipramine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Clomipramine.Approved, Illicit, Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Clomipramine.Approved, Investigational
GeldanamycinThe serum concentration of Clomipramine can be increased when it is combined with Geldanamycin.Experimental, Investigational
GemfibrozilThe metabolism of Clomipramine can be decreased when combined with Gemfibrozil.Approved
GemifloxacinClomipramine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepefrineClomipramine may increase the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Clomipramine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Clomipramine is combined with Glutethimide.Approved, Illicit
GM6001The serum concentration of Clomipramine can be increased when it is combined with GM6001.Experimental
GoserelinClomipramine may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Clomipramine.Approved, Investigational
GuanabenzClomipramine may decrease the antihypertensive activities of Guanabenz.Approved, Investigational
GuanfacineClomipramine may decrease the antihypertensive activities of Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Clomipramine is combined with Halazepam.Approved, Illicit, Withdrawn
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Clomipramine.Approved
HaloperidolThe metabolism of Clomipramine can be decreased when combined with Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Clomipramine.Approved, Vet Approved
HarmalineHarmaline may increase the serotonergic activities of Clomipramine.Experimental
HeroinThe risk or severity of adverse effects can be increased when Clomipramine is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe metabolism of Clomipramine can be increased when combined with Hexobarbital.Approved
HexoprenalineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Hexoprenaline.Approved, Withdrawn
HydracarbazineHydracarbazine may increase the serotonergic activities of Clomipramine.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Clomipramine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneClomipramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Clomipramine is combined with Hydroflumethiazide.Approved, Investigational
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Clomipramine.Approved, Illicit
HydroxyamphetamineClomipramine may increase the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.Approved
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Clomipramine.Approved
IbutilideClomipramine may increase the QTc-prolonging activities of Ibutilide.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Clomipramine.Approved
IdelalisibThe metabolism of Clomipramine can be decreased when combined with Idelalisib.Approved
IdraparinuxThe serum concentration of Clomipramine can be increased when it is combined with Idraparinux.Investigational
IloperidoneClomipramine may increase the QTc-prolonging activities of Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Clomipramine is combined with Iloprost.Approved, Investigational
ImatinibThe metabolism of Clomipramine can be decreased when combined with Imatinib.Approved
ImidaprilThe serum concentration of Clomipramine can be increased when it is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Clomipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Indacaterol.Approved
IndalpineIndalpine may increase the serotonergic activities of Clomipramine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Clomipramine is combined with Indapamide.Approved
IndinavirThe metabolism of Clomipramine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Clomipramine is combined with Indiplon.Investigational
IndoraminThe risk or severity of adverse effects can be increased when Clomipramine is combined with Indoramin.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Clomipramine.Approved, Investigational
Iofetamine I-123Clomipramine may increase the stimulatory activities of Iofetamine I-123.Approved
IpecacThe metabolism of Ipecac can be decreased when combined with Clomipramine.Approved, Withdrawn
IpratropiumThe metabolism of Ipratropium bromide can be decreased when combined with Clomipramine.Approved
IproclozideIproclozide may increase the serotonergic activities of Clomipramine.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Clomipramine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Clomipramine is combined with Irbesartan.Approved, Investigational
IsavuconazoleThe serum concentration of Clomipramine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Clomipramine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe therapeutic efficacy of Clomipramine can be increased when used in combination with Isocarboxazid.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Isoflurane.Approved, Vet Approved
IsoflurophateThe serum concentration of Clomipramine can be increased when it is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsomethepteneClomipramine may increase the vasopressor activities of Isometheptene.Approved
IsoniazidThe metabolism of Clomipramine can be decreased when combined with Isoniazid.Approved, Investigational
IsoprenalineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Isoprenaline.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Clomipramine is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Clomipramine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Clomipramine can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe metabolism of Clomipramine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Clomipramine can be increased when it is combined with Ivacaftor.Approved
IxazomibThe serum concentration of Clomipramine can be increased when it is combined with Ixazomib.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Clomipramine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Clomipramine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Clomipramine can be decreased when combined with Ketoconazole.Approved, Investigational
L-TryptophanL-Tryptophan may increase the serotonergic activities of Clomipramine.Approved, Nutraceutical, Withdrawn
LabetalolThe metabolism of Labetalol can be decreased when combined with Clomipramine.Approved
LacidipineClomipramine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Lamotrigine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Clomipramine.Approved
LenvatinibClomipramine may increase the QTc-prolonging activities of Lenvatinib.Approved, Investigational
LepirudinThe serum concentration of Clomipramine can be increased when it is combined with Lepirudin.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Lercanidipine.Approved, Investigational
LetaxabanThe serum concentration of Clomipramine can be increased when it is combined with Letaxaban.Investigational
LetermovirThe metabolism of Letermovir can be decreased when combined with Clomipramine.Approved, Investigational
LeuprolideClomipramine may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Clomipramine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Clomipramine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Levocetirizine.Approved
LevodopaClomipramine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinClomipramine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Clomipramine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the serotonergic activities of Clomipramine.Approved, Investigational
LevonordefrinClomipramine may decrease the antihypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Clomipramine.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Levosalbutamol.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Clomipramine is combined with Levosimendan.Approved, Investigational
LevothyroxineLevothyroxine may increase the arrhythmogenic activities of Clomipramine.Approved
LidocaineThe metabolism of Clomipramine can be decreased when combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Clomipramine can be increased when it is combined with Linagliptin.Approved
LinezolidLinezolid may increase the serotonergic activities of Clomipramine.Approved, Investigational
LiothyronineLiothyronine may increase the arrhythmogenic activities of Clomipramine.Approved, Vet Approved
LiotrixLiotrix may increase the arrhythmogenic activities of Clomipramine.Approved
LisdexamfetamineClomipramine may increase the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe serum concentration of Clomipramine can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Clomipramine.Approved, Investigational
Lithium cationLithium may increase the neurotoxic activities of Clomipramine.Experimental
LobeglitazoneThe metabolism of Clomipramine can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Clomipramine is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Clomipramine can be increased when used in combination with Lofexidine.Approved, Investigational
LomustineThe metabolism of Lomustine can be decreased when combined with Clomipramine.Approved, Investigational
LoperamideThe metabolism of Loperamide can be decreased when combined with Clomipramine.Approved
LopinavirThe metabolism of Clomipramine can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Clomipramine is combined with Loprazolam.Experimental
LoratadineThe metabolism of Loratadine can be decreased when combined with Clomipramine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Clomipramine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Clomipramine is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Clomipramine is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Clomipramine can be increased when it is combined with Lorpiprazole.Approved
LosartanThe risk or severity of adverse effects can be increased when Clomipramine is combined with Losartan.Approved
LovastatinThe metabolism of Clomipramine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Clomipramine.Approved
LuliconazoleThe serum concentration of Clomipramine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Clomipramine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineClomipramine may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Clomipramine.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Clomipramine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe metabolism of Clomipramine can be decreased when combined with Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Clomipramine.Approved, Investigational
MebanazineMebanazine may increase the serotonergic activities of Clomipramine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Clomipramine is combined with Mebicar.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Clomipramine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Clomipramine is combined with Medazepam.Experimental
MedetomidineClomipramine may decrease the antihypertensive activities of Medetomidine.Vet Approved
MelagatranThe serum concentration of Clomipramine can be increased when it is combined with Melagatran.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Clomipramine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Melperone.Approved, Investigational
MephedroneClomipramine may increase the stimulatory activities of Mephedrone.Investigational
MephentermineClomipramine may increase the vasopressor activities of Mephentermine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Clomipramine.Investigational, Withdrawn
MepivacaineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Clomipramine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Meptazinol.Experimental
MequitazineThe metabolism of Mequitazine can be decreased when combined with Clomipramine.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Clomipramine.Approved, Investigational
MetaraminolClomipramine may increase the vasopressor activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Clomipramine.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Clomipramine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Clomipramine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineClomipramine may decrease the antihypertensive activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Clomipramine is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Clomipramine.Approved, Vet Approved
MethohexitalThe metabolism of Clomipramine can be increased when combined with Methohexital.Approved
MethotrimeprazineClomipramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxamineClomipramine may increase the vasopressor activities of Methoxamine.Approved, Investigational
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Clomipramine.Approved, Investigational, Vet Approved
MethoxyphenamineClomipramine may increase the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Clomipramine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Clomipramine is combined with Methyclothiazide.Approved
MethyldopaClomipramine may decrease the antihypertensive activities of Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Methylecgonine.Experimental
Methylene blueClomipramine may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Clomipramine.Approved, Investigational
MethylphenobarbitalThe metabolism of Clomipramine can be increased when combined with Methylphenobarbital.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Clomipramine.Approved, Illicit, Withdrawn
MetipranololThe risk or severity of adverse effects can be increased when Clomipramine is combined with Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Clomipramine.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Clomipramine.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Clomipramine.Approved
MexiletineThe metabolism of Clomipramine can be decreased when combined with Mexiletine.Approved, Investigational
MianserinThe metabolism of Mianserin can be decreased when combined with Clomipramine.Approved, Investigational
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Clomipramine.Approved, Illicit
MidodrineClomipramine may increase the vasopressor activities of Midodrine.Approved
MidomafetamineClomipramine may increase the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Clomipramine can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Clomipramine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Clomipramine is combined with Milnacipran.Approved, Investigational
MinaprineMinaprine may increase the serotonergic activities of Clomipramine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Clomipramine is combined with Minoxidil.Approved, Investigational
MirabegronThe metabolism of Mirabegron can be decreased when combined with Clomipramine.Approved
MirtazapineClomipramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Clomipramine can be decreased when it is combined with Mitotane.Approved
MMDAClomipramine may increase the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideMoclobemide may increase the serotonergic activities of Clomipramine.Approved, Investigational
ModafinilThe metabolism of Clomipramine can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Clomipramine can be increased when it is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Moperone.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Clomipramine.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Morphine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Mosapramine.Experimental
MoxifloxacinClomipramine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Clomipramine.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Clomipramine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Clomipramine is combined with Nadolol.Approved
NafamostatThe serum concentration of Clomipramine can be increased when it is combined with Nafamostat.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Clomipramine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Clomipramine.Approved
NaphazolineClomipramine may decrease the antihypertensive activities of Naphazoline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Clomipramine.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Clomipramine.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Clomipramine.Approved, Investigational
NefazodoneThe metabolism of Clomipramine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Clomipramine can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Clomipramine is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Clomipramine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Clomipramine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic activities of Clomipramine.Withdrawn
NicardipineThe metabolism of Nicardipine can be decreased when combined with Clomipramine.Approved, Investigational
NicergolineThe metabolism of Nicergoline can be decreased when combined with Clomipramine.Approved, Investigational
NicorandilClomipramine may increase the hypotensive activities of Nicorandil.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Clomipramine.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Clomipramine.Approved
NilotinibClomipramine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Nilvadipine.Approved, Investigational
NimodipineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Nimodipine.Approved, Investigational
NisoldipineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Clomipramine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Clomipramine is combined with Nitric Oxide.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Clomipramine.Approved, Investigational, Vet Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Clomipramine is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Clomipramine is combined with Nitroprusside.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Clomipramine is combined with Nitrous acid.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Clomipramine.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Clomipramine is combined with Nordazepam.Approved
NorepinephrineClomipramine may decrease the antihypertensive activities of Norepinephrine.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Clomipramine.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Clomipramine is combined with Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the serotonergic activities of Clomipramine.Withdrawn
OfloxacinClomipramine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Clomipramine.Approved, Investigational
OlaparibThe metabolism of Clomipramine can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Clomipramine is combined with Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Olodaterol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clomipramine.Approved
OmapatrilatThe serum concentration of Clomipramine can be increased when it is combined with Omapatrilat.Investigational
OmeprazoleThe metabolism of Clomipramine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Clomipramine.Approved
OpiumThe risk or severity of adverse effects can be increased when Clomipramine is combined with Opium.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Orciprenaline.Approved
OrphenadrineClomipramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Clomipramine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Clomipramine can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Clomipramine can be increased when it is combined with Otamixaban.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Clomipramine.Approved
OxprenololThe risk or severity of adverse effects can be increased when Clomipramine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Clomipramine.Approved, Illicit, Investigational
OxymetazolineClomipramine may decrease the antihypertensive activities of Oxymetazoline.Approved, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Clomipramine.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Oxypertine.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Clomipramine is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Clomipramine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneClomipramine may decrease the antihypertensive activities of Paliperidone.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Clomipramine.Approved, Investigational
PanobinostatThe serum concentration of Clomipramine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Clomipramine can be decreased when combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Papaverine.Approved, Investigational
ParaldehydeClomipramine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylinePargyline may increase the serotonergic activities of Clomipramine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Clomipramine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Clomipramine.Approved
Peginterferon alfa-2bThe serum concentration of Clomipramine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Clomipramine is combined with Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Penfluridol.Experimental
PentamidineThe metabolism of Pentamidine can be decreased when combined with Clomipramine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Clomipramine.Approved, Vet Approved
PentobarbitalThe metabolism of Clomipramine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Clomipramine.Approved, Investigational
PerflutrenClomipramine may increase the QTc-prolonging activities of Perflutren.Approved
PergolideClomipramine may decrease the antihypertensive activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Clomipramine.Approved, Investigational
PerindoprilThe serum concentration of Clomipramine can be increased when it is combined with Perindopril.Approved
PerospironeThe metabolism of Perospirone can be decreased when combined with Clomipramine.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Clomipramine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Clomipramine.Approved
PF-00610355The risk or severity of adverse effects can be increased when Clomipramine is combined with PF-00610355.Investigational
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Clomipramine.Withdrawn
PhenazocineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Phenazocine.Experimental
PhendimetrazineClomipramine may increase the vasopressor activities of Phendimetrazine.Approved, Illicit
PhenelzinePhenelzine may increase the serotonergic activities of Clomipramine.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Clomipramine.Approved, Investigational, Withdrawn
PhenibutThe risk or severity of adverse effects can be increased when Clomipramine is combined with Phenibut.Experimental
PhenindioneClomipramine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazinePheniprazine may increase the serotonergic activities of Clomipramine.Withdrawn
PhenobarbitalThe metabolism of Clomipramine can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Phenoperidine.Experimental
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Phenoxyethanol.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Clomipramine.Withdrawn
PhenprocoumonClomipramine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhentermineClomipramine may increase the stimulatory activities of Phentermine.Approved, Illicit
PhentolamineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Phentolamine.Approved
PhenylephrineClomipramine may increase the vasopressor activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Clomipramine can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Clomipramine can be increased when it is combined with Phosphoramidon.Experimental
PimozideClomipramine may increase the QTc-prolonging activities of Pimozide.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Clomipramine.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Pipamperone.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Clomipramine.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Clomipramine.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Clomipramine is combined with Piritramide.Approved, Investigational
PirlindolePirlindole may increase the serotonergic activities of Clomipramine.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Clomipramine.Approved, Investigational
PivhydrazinePivhydrazine may increase the serotonergic activities of Clomipramine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Clomipramine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Clomipramine is combined with Pomalidomide.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Clomipramine.Approved, Investigational
PosaconazoleThe metabolism of Clomipramine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleClomipramine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Clomipramine is combined with Prazepam.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Clomipramine is combined with Prazosin.Approved
PregabalinThe therapeutic efficacy of Clomipramine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Prilocaine.Approved
PrimaquineClomipramine may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Clomipramine can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Clomipramine can be increased when it is combined with Prinomastat.Investigational
ProcainamideClomipramine may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineProcaine may increase the serotonergic activities of Clomipramine.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the serotonergic activities of Clomipramine.Approved, Investigational
ProcaterolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Procaterol.Approved, Investigational
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Clomipramine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Clomipramine.Approved, Vet Approved
PromazineThe metabolism of Clomipramine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Clomipramine.Approved, Investigational
PropafenoneThe serum concentration of Clomipramine can be increased when it is combined with Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Clomipramine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Proparacaine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Clomipramine.Approved, Investigational
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Clomipramine.Vet Approved
PropofolThe metabolism of Propofol can be decreased when combined with Clomipramine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Propoxycaine.Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Clomipramine.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Clomipramine is combined with Prothipendyl.Investigational
ProtokylolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Protokylol.Approved, Vet Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Clomipramine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Clomipramine is combined with Proxibarbal.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Clomipramine.Approved
PSD502The risk or severity of adverse effects can be increased when Clomipramine is combined with PSD502.Investigational
PseudoephedrineClomipramine may decrease the antihypertensive activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Clomipramine.Approved, Illicit
QuetiapineClomipramine may increase the QTc-prolonging activities of Quetiapine.Approved
QuinaprilThe serum concentration of Clomipramine can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineClomipramine may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
QuinineClomipramine may increase the QTc-prolonging activities of Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Quinisocaine.Experimental
RacecadotrilThe serum concentration of Clomipramine can be increased when it is combined with Racecadotril.Investigational
RacepinephrineClomipramine may decrease the antihypertensive activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Clomipramine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Clomipramine.Approved, Investigational
RamiprilThe serum concentration of Clomipramine can be increased when it is combined with Ramipril.Approved
RanitidineThe metabolism of Ranitidine can be decreased when combined with Clomipramine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Clomipramine.Approved, Investigational
RasagilineRasagiline may increase the serotonergic activities of Clomipramine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Clomipramine is combined with Remifentanil.Approved
RemikirenThe serum concentration of Clomipramine can be increased when it is combined with Remikiren.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Clomipramine.Approved, Withdrawn
RepinotanThe metabolism of Repinotan can be decreased when combined with Clomipramine.Investigational
ReserpineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Reserpine.Approved, Investigational
RifabutinThe metabolism of Clomipramine can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Clomipramine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Clomipramine can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Clomipramine.Approved, Investigational
RiociguatThe risk or severity of adverse effects can be increased when Clomipramine is combined with Riociguat.Approved
RisperidoneClomipramine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Clomipramine is combined with Ritanserin.Investigational
RitobegronClomipramine may increase the stimulatory activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Ritodrine.Approved, Investigational
RitonavirThe metabolism of Clomipramine can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Clomipramine can be increased when it is combined with Rivaroxaban.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Clomipramine.Approved
RolapitantThe metabolism of Clomipramine can be decreased when combined with Rolapitant.Approved, Investigational
RomifidineClomipramine may decrease the antihypertensive activities of Romifidine.Vet Approved
RopiniroleClomipramine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Clomipramine.Approved
RotigotineClomipramine may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Rucaparib can be decreased when combined with Clomipramine.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Clomipramine.Approved
RupatadineThe metabolism of Rupatadine can be decreased when combined with Clomipramine.Approved
S-3304The serum concentration of Clomipramine can be increased when it is combined with S-3304.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Clomipramine is combined with Sacubitril.Approved
SafrazineSafrazine may increase the serotonergic activities of Clomipramine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Salmeterol.Approved
SaquinavirThe metabolism of Clomipramine can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Clomipramine can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe serum concentration of Clomipramine can be increased when it is combined with Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Clomipramine.Approved, Investigational
SecobarbitalThe metabolism of Clomipramine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the serotonergic activities of Clomipramine.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Sepranolone.Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Clomipramine.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Clomipramine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Clomipramine can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Clomipramine.Approved
SiltuximabThe serum concentration of Clomipramine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Clomipramine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Clomipramine.Approved
SitagliptinThe serum concentration of Clomipramine can be increased when it is combined with Sitagliptin.Approved, Investigational
SivelestatThe serum concentration of Clomipramine can be increased when it is combined with Sivelestat.Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.Approved
Sodium phosphate, monobasicThe risk or severity of adverse effects can be increased when Clomipramine is combined with Sodium phosphate.Approved
SotalolClomipramine may increase the QTc-prolonging activities of Sotalol.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Clomipramine.Experimental
SpiraprilThe serum concentration of Clomipramine can be increased when it is combined with Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Spironolactone.Approved
St. John's WortThe metabolism of Clomipramine can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Clomipramine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Clomipramine is combined with Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Clomipramine is combined with Sufentanil.Approved, Investigational
SulfisoxazoleThe metabolism of Clomipramine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Clomipramine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Clomipramine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Clomipramine.Approved, Investigational
SuvorexantClomipramine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Clomipramine.Approved, Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Clomipramine resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Clomipramine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Clomipramine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Clomipramine is combined with Tasimelteon.Approved, Investigational
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Clomipramine.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Clomipramine.Approved, Investigational, Withdrawn
TelaprevirThe metabolism of Clomipramine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelavancinClomipramine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Clomipramine can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Clomipramine is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Clomipramine.Approved, Investigational
TemocaprilThe serum concentration of Clomipramine can be increased when it is combined with Temocapril.Experimental, Investigational
Tenofovir disoproxilThe metabolism of Clomipramine can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Clomipramine is combined with Terazosin.Approved
TerbinafineThe metabolism of Clomipramine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Terbutaline.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Clomipramine.Approved, Withdrawn
TeriflunomideThe serum concentration of Clomipramine can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Clomipramine.Investigational
TetrabenazineClomipramine may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Clomipramine is combined with Tetrodotoxin.Investigational
TetryzolineClomipramine may increase the vasopressor activities of Tetryzoline.Approved
ThalidomideClomipramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Clomipramine can be decreased when combined with Theophylline.Approved
ThiamylalThe metabolism of Clomipramine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Thiazinam is combined with Clomipramine.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Clomipramine.Withdrawn
ThiopentalThe metabolism of Clomipramine can be increased when combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Clomipramine is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Clomipramine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Clomipramine.Approved, Withdrawn
ThiorphanThe serum concentration of Clomipramine can be increased when it is combined with Thiorphan.Experimental
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Clomipramine.Approved
Thyroid, porcineThyroid, porcine may increase the arrhythmogenic activities of Clomipramine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Clomipramine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Clomipramine is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Clomipramine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Tilidine.Experimental
TimololThe metabolism of Timolol can be decreased when combined with Clomipramine.Approved
TioclomarolClomipramine may increase the anticoagulant activities of Tioclomarol.Experimental
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Clomipramine.Approved
TipranavirThe metabolism of Clomipramine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineClomipramine may decrease the antihypertensive activities of Tizanidine.Approved, Investigational
TocilizumabThe serum concentration of Clomipramine can be decreased when it is combined with Tocilizumab.Approved
TolazolineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Clomipramine is combined with Tolcapone.Approved, Withdrawn
ToloxatoneToloxatone may increase the serotonergic activities of Clomipramine.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Clomipramine.Approved, Investigational
TopiramateThe metabolism of Clomipramine can be decreased when combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Clomipramine.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Clomipramine is combined with Torasemide.Approved
ToremifeneClomipramine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Clomipramine.Approved, Investigational
TramadolClomipramine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
TrandolaprilThe serum concentration of Clomipramine can be increased when it is combined with Trandolapril.Approved
TranylcypromineTranylcypromine may increase the serotonergic activities of Clomipramine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Clomipramine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Clomipramine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Clomipramine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Clomipramine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Clomipramine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Clomipramine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Clomipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Clomipramine.Approved
TropisetronTropisetron may increase the serotonergic activities of Clomipramine.Approved, Investigational
UbenimexThe serum concentration of Clomipramine can be increased when it is combined with Ubenimex.Experimental, Investigational
UlinastatinThe serum concentration of Clomipramine can be increased when it is combined with Ulinastatin.Investigational
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Clomipramine.Approved
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Clomipramine.Approved, Investigational
Valproic AcidThe serum concentration of Clomipramine can be increased when it is combined with Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Clomipramine is combined with Valsartan.Approved, Investigational
VandetanibClomipramine may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Clomipramine.Approved
VenlafaxineVenlafaxine may increase the serotonergic activities of Clomipramine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Clomipramine is combined with Veralipride.Experimental
VerapamilThe metabolism of Clomipramine can be decreased when combined with Verapamil.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Clomipramine.Approved, Investigational
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Clomipramine.Approved
VilanterolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Vilanterol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Clomipramine.Approved
VildagliptinThe serum concentration of Clomipramine can be increased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe metabolism of Vinblastine can be decreased when combined with Clomipramine.Approved
VincristineThe excretion of Vincristine can be decreased when combined with Clomipramine.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Clomipramine.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Clomipramine is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Clomipramine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Clomipramine.Approved, Investigational
WarfarinClomipramine may increase the anticoagulant activities of Warfarin.Approved
XenonThe risk or severity of adverse effects can be increased when Clomipramine is combined with Xenon.Experimental
XimelagatranThe serum concentration of Clomipramine can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineClomipramine may decrease the antihypertensive activities of Xylazine.Vet Approved
XylometazolineClomipramine may decrease the antihypertensive activities of Xylometazoline.Approved, Investigational
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Clomipramine.Approved, Investigational, Vet Approved
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Clomipramine can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Clomipramine.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Clomipramine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Clomipramine is combined with Ziconotide.Approved
ZimelidineZimelidine may increase the serotonergic activities of Clomipramine.Withdrawn
ZiprasidoneClomipramine may increase the QTc-prolonging activities of Ziprasidone.Approved
ZofenoprilThe serum concentration of Clomipramine can be increased when it is combined with Zofenopril.Experimental
ZolazepamThe risk or severity of adverse effects can be increased when Clomipramine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Clomipramine.Approved, Investigational
ZolpidemClomipramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Clomipramine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Clomipramine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Zotepine.Approved, Investigational, Withdrawn
ZucapsaicinThe metabolism of Clomipramine can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolClomipramine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Grapefruit and grapefruit juice should be avoided throughout treatment, grapefruit can modify serum levels of clomipramine and its metabolite desmethyl-clomipramine.
  • Take with food to reduce irritation.

References

Synthesis Reference

Schindler, W. and Dietrich, H.; US. Patent 3,515,785; June 2,1970; assigned to Geigy Chemical Corp.

General References
Not Available
External Links
Human Metabolome Database
HMDB0015372
KEGG Drug
D00811
KEGG Compound
C06918
PubChem Compound
2801
PubChem Substance
46505157
ChemSpider
2699
BindingDB
77970
ChEBI
47780
ChEMBL
CHEMBL415
Therapeutic Targets Database
DAP000742
PharmGKB
PA449048
IUPHAR
2398
Guide to Pharmacology
GtP Drug Page
HET
CXX
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Clomipramine
ATC Codes
N06AA04 — Clomipramine
AHFS Codes
  • 28:16.04.28 — Tricyclics and Other Norepinephrine-reuptake Inhibitors
PDB Entries
2q6h / 2qei / 4mma / 6g9i
FDA label
Download (712 KB)
MSDS
Download (74.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentDepression1
1CompletedTreatmentHealthy Volunteers1
2CompletedTreatmentBack Pain1
2CompletedTreatmentBack Pain / Sciatica1
2CompletedTreatmentPremature Ejaculation1
2Unknown StatusTreatmentObsessive-Compulsive Disorder (OCD)1
3CompletedTreatmentObsessive Compulsive Disorder (OCD)1
3CompletedTreatmentPremature Ejaculation1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
4CompletedTreatmentObsessive Compulsive Disorder (OCD)2
Not AvailableCompletedNot AvailableObsessive Compulsive Disorder (OCD)1
Not AvailableCompletedBasic ScienceMajor Depressive Disorder (MDD)1
Not AvailableCompletedTreatmentDepression1
Not AvailableUnknown StatusTreatmentTreatment Resistant Depression (TRD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Abic Ltd.
  • Basel Pharmaceuticals Div Ciba Geigy Corp.
  • Comprehensive Consultant Services Inc.
  • Dispensing Solutions
  • Gallipot
  • Heartland Repack Services LLC
  • Mallinckrodt Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Novartis AG
  • Novopharm Ltd.
  • Nucare Pharmaceuticals Inc.
  • Patheon Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmacy Service Center
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Remedy Repack
  • Sandoz
  • Taro Pharmaceuticals USA
  • Teva Pharmaceutical Industries Ltd.
Dosage forms
FormRouteStrength
CapsuleOral25 mg/1
CapsuleOral50 mg/1
CapsuleOral75 mg/1
TabletOral10 mg
TabletOral25 mg
TabletOral50 mg
Prices
Unit descriptionCostUnit
Clomipramine hcl powder17.88USD g
Anafranil 25 mg capsule13.51USD capsule
Anafranil 50 mg capsule13.51USD capsule
Anafranil 75 mg capsule13.24USD capsule
ClomiPRAMINE HCl 75 mg capsule1.55USD capsule
Clomipramine 75 mg capsule1.33USD capsule
Clomipramine 50 mg capsule1.01USD capsule
ClomiPRAMINE HCl 25 mg capsule0.88USD capsule
Anafranil 50 mg Tablet0.77USD tablet
Clomipramine 25 mg capsule0.75USD capsule
ClomiPRAMINE HCl 50 mg capsule0.57USD capsule
Apo-Clomipramine 50 mg Tablet0.43USD tablet
Co Clomipramine 50 mg Tablet0.43USD tablet
Anafranil 25 mg Tablet0.42USD tablet
Anafranil 10 mg Tablet0.31USD tablet
Apo-Clomipramine 25 mg Tablet0.23USD tablet
Co Clomipramine 25 mg Tablet0.23USD tablet
Apo-Clomipramine 10 mg Tablet0.17USD tablet
Co Clomipramine 10 mg Tablet0.17USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)191.5-192Schindler, W. and Dietrich, H.; US. Patent 3,515,785; June 2,1970; assigned to Geigy Chemical Corp.
boiling point (°C)160-170 °C at 3.00E-01 mm HgPhysProp
water solubility0.294 mg/LNot Available
logP5.19HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0144 mg/mLALOGPS
logP5.04ALOGPS
logP4.88ChemAxon
logS-4.3ALOGPS
pKa (Strongest Basic)9.2ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity95.41 m3·mol-1ChemAxon
Polarizability35.73 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9843
Blood Brain Barrier+0.9793
Caco-2 permeable+0.8391
P-glycoprotein substrateSubstrate0.7618
P-glycoprotein inhibitor IInhibitor0.8573
P-glycoprotein inhibitor IIInhibitor0.8387
Renal organic cation transporterInhibitor0.852
CYP450 2C9 substrateNon-substrate0.7875
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7408
CYP450 1A2 substrateInhibitor0.8374
CYP450 2C9 inhibitorNon-inhibitor0.9176
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.7971
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6074
Ames testNon AMES toxic0.8735
CarcinogenicityNon-carcinogens0.8971
BiodegradationNot ready biodegradable0.9967
Rat acute toxicity2.7426 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.889
hERG inhibition (predictor II)Inhibitor0.8029
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-066r-6391000000-e57dc447a97807ce527a
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-052r-9010000000-77a0afe2d49df71431d8
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-2009000000-a1cc70dad4bb4c19ab7b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-9000000000-a9af3369f8d6da434fd0
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-052r-9000000000-3f1941447bc096ea9d73
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4r-9010000000-c6b5c5a56ac456cd8845
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-9010000000-8b5307526ea875a06881
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-9010000000-98746d4db184914ce871
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-9310000000-194486cca11709cd1b80
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-9600000000-da861dd5252aaff30e89
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-6900000000-efdead8e50e8b700d4bd
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-00di-0090000000-558a68c9d4919e7945a2
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-00di-0090000000-489c71d87d96f5bafd40
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-014i-0009002000-3318f523b446a8d9d68e
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-014i-0009000000-8b8a1763c5358415b2b0

Taxonomy

Description
This compound belongs to the class of organic compounds known as dibenzazepines. These are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzazepines
Sub Class
Dibenzazepines
Direct Parent
Dibenzazepines
Alternative Parents
Alkyldiarylamines / Azepines / Benzenoids / Aryl chlorides / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organochlorides / Hydrocarbon derivatives
Substituents
Dibenzazepine / Alkyldiarylamine / Tertiary aliphatic/aromatic amine / Azepine / Benzenoid / Aryl halide / Aryl chloride / Tertiary aliphatic amine / Tertiary amine / Azacycle
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
dibenzoazepine (CHEBI:47780)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Alvarez JC, Gluck N, Arnulf I, Quintin P, Leboyer M, Pecquery R, Launay JM, Perez-Diaz F, Spreux-Varoquaux O: Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: effects of clomipramine and fluoxetine. Clin Pharmacol Ther. 1999 Dec;66(6):617-24. [PubMed:10613618]
  2. Borkowska A, Pilaczynska E, Araszkiewicz A, Rybakowski J: [The effect of sertraline on cognitive functions in patients with obsessive-compulsive disorder]. Psychiatr Pol. 2002 Nov-Dec;36(6 Suppl):289-95. [PubMed:12647451]
  3. Suhara T, Takano A, Sudo Y, Ichimiya T, Inoue M, Yasuno F, Ikoma Y, Okubo Y: High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry. 2003 Apr;60(4):386-91. [PubMed:12695316]
  4. Larsen AK, Brennum LT, Egebjerg J, Sanchez C, Halldin C, Andersen PH: Selectivity of (3)H-MADAM binding to 5-hydroxytryptamine transporters in vitro and in vivo in mice; correlation with behavioural effects. Br J Pharmacol. 2004 Mar;141(6):1015-23. Epub 2004 Mar 1. [PubMed:14993096]
  5. Malizia AL, Melichar JM, Brown DJ, Gunn RN, Reynolds A, Jones T, Nutt DJ: Demonstration of clomipramine and venlafaxine occupation at serotonin reuptake sites in man in vivo. J Psychopharmacol. 1997;11(3):279-81. [PubMed:9305421]
  6. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
  7. Gillman PK: Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007 Jul;151(6):737-48. Epub 2007 Apr 30. [PubMed:17471183]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Hentall ID, Kurle PJ, White TR: Correlations between serotonin level and single-cell firing in the rat's nucleus raphe magnus. Neuroscience. 2000;95(4):1081-8. [PubMed:10682715]
  2. Contreras CM, Marvan ML, Munoz-Mendez A, Ramirez-Morales A: Cortical and septal responses to dorsal raphe nucleus stimulation in the rat: long-term clomipramine actions. Bol Estud Med Biol. 1992 Jan-Dec;40(1-4):3-7. [PubMed:1296670]
  3. Sugimoto Y, Inoue K, Yamada J: The tricyclic antidepressant clomipramine increases plasma glucose levels of mice. J Pharmacol Sci. 2003 Sep;93(1):74-9. [PubMed:14501155]
  4. Trifunovic RD, Brodie MS: The effects of clomipramine on the excitatory action of ethanol on dopaminergic neurons of the ventral tegmental area in vitro. J Pharmacol Exp Ther. 1996 Jan;276(1):34-40. [PubMed:8558452]
  5. Sargent PA, Quested DJ, Cowen PJ: Clomipramine enhances the cortisol response to 5-HTP: implications for the therapeutic role of 5-HT2 receptors. Psychopharmacology (Berl). 1998 Nov;140(1):120-2. [PubMed:9862411]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation...
Gene Name
HTR2B
Uniprot ID
P41595
Uniprot Name
5-hydroxytryptamine receptor 2B
Molecular Weight
54297.41 Da
References
  1. Sargent PA, Quested DJ, Cowen PJ: Clomipramine enhances the cortisol response to 5-HTP: implications for the therapeutic role of 5-HT2 receptors. Psychopharmacology (Berl). 1998 Nov;140(1):120-2. [PubMed:9862411]
  2. Sugimoto Y, Inoue K, Yamada J: The tricyclic antidepressant clomipramine increases plasma glucose levels of mice. J Pharmacol Sci. 2003 Sep;93(1):74-9. [PubMed:14501155]
  3. Contreras CM, Marvan ML, Munoz-Mendez A, Ramirez-Morales A: Cortical and septal responses to dorsal raphe nucleus stimulation in the rat: long-term clomipramine actions. Bol Estud Med Biol. 1992 Jan-Dec;40(1-4):3-7. [PubMed:1296670]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Sargent PA, Quested DJ, Cowen PJ: Clomipramine enhances the cortisol response to 5-HTP: implications for the therapeutic role of 5-HT2 receptors. Psychopharmacology (Berl). 1998 Nov;140(1):120-2. [PubMed:9862411]
  2. Sugimoto Y, Inoue K, Yamada J: The tricyclic antidepressant clomipramine increases plasma glucose levels of mice. J Pharmacol Sci. 2003 Sep;93(1):74-9. [PubMed:14501155]
  3. Contreras CM, Marvan ML, Munoz-Mendez A, Ramirez-Morales A: Cortical and septal responses to dorsal raphe nucleus stimulation in the rat: long-term clomipramine actions. Bol Estud Med Biol. 1992 Jan-Dec;40(1-4):3-7. [PubMed:1296670]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
  2. Jungkun G, Kuss HJ, Gsell W: Long-term effects of tricyclic antidepressants on norepinephrine kinetics in humans. J Neural Transm (Vienna). 2001;108(3):349-62. [PubMed:11341486]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
S-nitrosoglutathione binding
Specific Function
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Regulates negatively CDK5 activity via p25/p35 translocation to prevent neurodegeneration.
Gene Name
GSTP1
Uniprot ID
P09211
Uniprot Name
Glutathione S-transferase P
Molecular Weight
23355.625 Da
References
  1. Baranczyk-Kuzma A, Sawicki J, Kuzma M, Jagiello J: [Tricyclic antidepressants as inhibitors of brain glutathione-S-transferase]. Pol Merkur Lekarski. 2001 Dec;11(66):472-5. [PubMed:11899840]
  2. Baranczyk-Kuzma A, Kuzma M, Gutowicz M, Kazmierczak B, Sawicki J: Glutathione S-transferase pi as a target for tricyclic antidepressants in human brain. Acta Biochim Pol. 2004;51(1):207-12. [PubMed:15094841]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
  3. The P450 Program [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
  3. Source [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. The P450 Program [Link]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524]

Drug created on June 13, 2005 07:24 / Updated on July 13, 2018 01:07